Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126022 · ClinicalTrials.gov registry record · Phase 3
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
A Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00126022 is a Phase 3 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Solvay Pharmaceuticals. The trial reports 20 study locations across 2 states.
The verdict
NCT00126022, a Phase 3 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.
Conditions Studied
Interventions
- DRUG Tedisamil sesquifumarate
Study Locations (20)
Other
- Site 2 - Buenos Aires
- Site 3 - Buenos Aires
- Site 5 - Munro
- Site 4 - San Miguel de Tucumán
- Site 8 - Brno
- Site 11 - Jindřichův Hradec
- Site 9 - Ostrava-Poruba
- Site 10 - Pilsen
- Site 14 - Prague
- Site 6 - Prague
- Site 7 - Prague
- Site 12 - Slaný
- Site 13 - Ústí nad Orlicí
- Site 15 - Bad Nauheim
- Site 17 - Göttingen
- Site 16 - Halle
- Site 18 - Haifa
- Site 19 - Jerusalem
- Site 22 - Jerusalem
Tennessee
- Site 82 - Tullahoma
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126022
The ClinicalTrials.gov registry entry for NCT00126022 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Tedisamil sesquifumarate is the first listed.
NCT00126022 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00126022 about?
NCT00126022 is a clinical study titled "Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects". The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.
What is the current status of trial NCT00126022?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-12. Estimated completion is 2006-03.
What conditions does trial NCT00126022 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT00126022?
The interventions under investigation include: Tedisamil sesquifumarate (DRUG).
Who is sponsoring clinical trial NCT00126022?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00126022 being conducted?
This trial has 20 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.